We are Sorry, This Page doesn't Exist
Bristol-Myers Squibb"s stock gains 2% after adjusted earnings beat
Shares of Bristol-Myers Squibb gained 2.6% in premarket trading on Thursday after the drugmaker posted stronger-than-ex.....»»
Bristol-Myers is a buy during the coronavirus outbreak
Bristol-Myers Squibb shares remain quite cheap on a forward looking basis, offering potential strong double digit returns in 2020......»»
Bristol-Myers posts better-than-expected results, Opdivo growth slows
U.S. drugmaker Bristol-Myers Squibb Co reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed......»»
Bristol-Myers Squibb"s Revenues: How Does Bristol-Myers Squibb Make Money?
Bristol Myers S.....»»
Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia......»»
Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise
Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise.....»»
Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis
Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong perfor.....»»
Bristol-Myers profit slightly tops Wall Street view on blood thinner sales
U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis......»»
Bristol-Myers Squibb (BMY) Q1 Earnings and Revenues Top Estimates
Bristol-Myers (BMY) delivered earnings and revenue surprises of 0.92% and 2.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Zacks Inve.....»»
The Bristol-Myers--Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
Amid strong opposition to the Big Pharma merger, Bristol-Myers faces three scenarios, none of them pretty, writes UBS’s Navin Jacob......»»
Bayer cuts full-year earnings guidance on strong euro
Bayer says the pressure from a stronger euro on overseas revenues would translate into a decline in earnings this year, as it prepares to close its $62.5 billion takeover of U.S. seeds maker Monsanto next quarter. Sonia Legg reports......»»
What Tariffs? Caterpillar Is Doing So Well It Is Raising Prices
Caterpillar had a stronger-than-expected quarter, with revenues and profits beating consensus estimates. The company sees some impact from tariffs, but sales remain strong enough for it to raise........»»
Merck, Bristol-Myers profits rise on cancer drug sales
Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments......»»
Bristol-Myers says commitment to Opdivo "strong"
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
The US dollar is so strong that China"s central bank, among others, just keeps loading up on gold
Not just China, but other central banks including Turkey and India are loading up on gold, amid a stronger .....»»
Gray Television Projects Higher Political Ad Revenues Amid Election Year - Read Why
Gray Television anticipates increased political revenues for Q2 2024, supported by strong core advertising and demand for local content. read more.....»»
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
Latest Ratings for BMY .....»»
Bristol Myers Squibb to close big Peninsula site, consolidate at another amid company-wide cuts
The company says it will cut 2,200 jobs this year on its way to shedding $1.5 billion in costs by the end of next year......»»
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05. read more.....»»
IBM"s Moment Of Truth As Earnings Expected To Impress With Strong AI Influence, Analyst Says
IBM (NYSE:IBM) reports Q1 earnings on April 24, with EPS of $1.59 and $14.6B in revenues expected. Stock up 45% in past year. BofA analyst maintains Buy rating and $220 price target. Latest Rati.....»»